No Detail Found!

Clinical eficacy of Apatinib combined with Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) in nonsmall cell lung cancer after EGFR-TKI resistance

Author(s)
Ruifen Tian Department of Respiratory Medicine, Shanxi Tumour Hospital, 3 Zhigongxin Village, Taiyuan, Shanxi Province 030013, P.R. China.
Yi Guo Department of Respiratory Medicine, Shanxi Tumour Hospital, 3 Zhigongxin Village, Taiyuan, Shanxi Province 030013, P.R. China.
Xing Zhang Department of Respiratory Medicine, Shanxi Tumour Hospital, 3 Zhigongxin Village, Taiyuan, Shanxi Province 030013, P.R. China.
Xia Zhang Department of Respiratory Medicine, Shanxi Tumour Hospital, 3 Zhigongxin Village, Taiyuan, Shanxi Province 030013, P.R. China.
Xia Song Department of Respiratory Medicine, Shanxi Tumour Hospital, 3 Zhigongxin Village, Taiyuan, Shanxi Province 030013, P.R. China.
Abstract
Objective: To evaluate the eficacy and safety of Apatinib combined with epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) in the treatment of patients with non-small cell lung cancer (NSCLC) and acquired EGFRTKI resistance. Methods: Clinical records of 106 patients with NSCLC at Shanxi Tumor Hospital of the Chinese Academy of Medical Sciences Cancer Hospital from January 2017 to October 2020, with acquired drug resistance after EGFR-TKI treatment were retrospectively analyzed. Among them, 52 patients received Apatinib combined with EGFR-TKI (Apatinib group), and 54 patients received a standard chemotherapy (pemetrexed combined with platinum) (chemotherapy group). Clinical eficacy indicators, follow-up results, and adverse reactions in both groups were compared. Results: There was no significant diference in the objective response rate and disease control rate between the two groups (P>0.05). The progression free survival (PFS) of the Apatinib group was significantly longer than that of the chemotherapy group (10.5 months vs. 5.7 months; P0.05). Conclusions: Compared with standard chemotherapy, Apatinib combined with EGFR-TKI has the same eficacy in treating NSCLC patients with EGFR-TKI resistance, and was associated with longer PFS with no significant increase in adverse reactions.
Publication Details
Page(s) 1714-1718
Published Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
Resistance, Non-small Cell Lung Cancer, Epidermal growth factor receptor, apatinib, Tyrosine kinase inhibitor
References
Jiao J,Li WW,Shang YH,Li XF,Jiao M. .2023 .Clinical effects of Chemotherapy combined with Immunotherapy in patients with advanced NSCLC and the effect on their nutritional status and immune function. Pak J Med Sci, 10(2) : 6365-408.
Chen P,Liu Y,Wen Y,Zhou C .2022 .Non-small cell lung cancer in China. Cancer Commun (Lond), 10(10) : 937-970.
Siegel RL,Miller KD,Fuchs HE,Jemal A .2021 .. , 10(1) : 7-33.
Wu SG,Shih JY .2018 .Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer, 10(1) : 38.
Costa C,Molina MA,Drozdowskyj A,Giménez-Capitán A,Bertran-Alamillo J,Karachaliou N .2014 .The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res, 10(7) : CCR13-2233.
Bethune G,Bethune D,Ridgway N .2010 .Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis, 2(1) : 48-51.
Cho BC,Han JY,Kim SW,Lee KH,Cho EK,Lee YG,Oncol J Thorac .2021 .A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. , 11(4) : 558-567.
Elebiyo TC,Rotimi D,Evbuomwan IO,Maimako RF,Iyobhebhe M,Ojo OA .2022 .Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treat Res Commun, 10 : 100620.
Su JL,Yen CJ,Chen PS,Chuang SE,Hong CC,Kuo IH .2007 .The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer, 10(4) : 541-545.
Zhang C,Wu T,Shen N. .2022 .Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin. Pak J Med Sci, 10(8) : 6786-2168.
Cui YJ,Liu J,Liu MM,Zhang HZ .2021 .Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Pak J Med Sci, 10(4) : 4066-1041.
Yue-Yun C,Ye H,Yang F,Qing L,Pan-Pan L,Zhen-Yu D. Sequential L,Pac J Cancer Prev L .2019 .Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. , 20(8) : 2415-2420.
Liu M,Li X,Zhang H,Ren F,Liu J,Li Y .2023 .Apatinib added when NSCLC patients get slow progression with EGFR-TKI: A prospective, single-arm study. Cancer Med, 10(24) : 21735-21741.
.2010 .Common Terminology Criteria for Adverse Events (CTCAE) v4. , : 0.
Li F,Zhu T,Cao B,Wang J,Liang L .2017 .Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFRTKI resistance. Eur J Cancer, 07 : 184-192.
Yu Y,Wang Y,Wu L,Xu X,Zhou H,Wang Q .2021 .Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFRTKIs) combined with bevacizumab for advanced non squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study. Medicine (Baltimore), 10(5) : .
Melincovici CS,Boşca AB,Şuşman S,Mărginean M,Mihu C,Istrate M .2018 .Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol, 59(2) : 455-467.
Osude C,Lin L,Patel M,Eckburg A,Berei J,Kuckovic A .2022 .Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer. Cells, 10(10) : 1694.
Zhu N,Dong C,Weng S,Yuan Y,Yuan Y. .2019 .A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs. J Coll Physicians Surg Pak, 12(12) : S126-S128.
Su J,Zhao Q,Zheng Z,Wang H,Bian C,Meng L .2022 .Prospective Application of Ferroptosis in Hypoxic Cells for Tumor Radiotherapy. Antioxidants (Basel), 10(5) : 921.
Lin WP,Xing KL,Fu JC,Ling YH,Li SH,Yu WS .2021 .Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma. , 10(9) : .
Zhao H,Yao W,Min X,Gu K,Yu G,Zhang Z,Mutant NSCLC .2021 .The Phase III ACTIVE Study (CTONG1706). J Thorac Oncol, 05(9) : 1533-1546.
0

Citations

0

Downloads

72

Views